Business
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of Euro1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Mil...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, July 4, 2019\n\n\n\nLAVAL, QC, July 4, 2019 /CNW/ - Crescita Therapeutics Inc. (\"Crescita\" or the \"Company\") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has received the second instalment of € $1.25 million (~CDN $1.88 million) of the up-front payment related to the out-licensing of Pliaglis in Italy, France, Spain and Portugal, from its partner, Cantabria Labs. The 2nd instalment was received following the completion of the transition activities from Galderma to Cantabria  leading to the first commercial sale of Pliaglis in Italy by the Cantabria sales team.\n\n \n \n\n \n\"We are delighted with how smoothly the transition was completed,\" said Serge Verreault, President and CEO of Crescita. \"Receiving the second instalment solidifies our cash position and allows us to be opportunistic in the pursuit of accretive acquisition targets as we continue executing our four-pillar growth strategy.\" \nAbout Crescita Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.\nAbout Cantabria Labs Cantabria Labs is a pharmaceutical company with subsidiaries in Spain, Italy, Portugal, France, Mexico, Morocco and China. With it...